Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.

Journal article

The Akt activation inhibitor triciribine and the farnesyltransferase inhibitor tipifarnib have modest to little activity in clinical trials when used as single agents. In this article, preclinical data show that the combination is more effective than single agents both in cultured cells and in vivo. Combination index data analysis shows that this combination is highly synergistic at inhibiting anchorage-dependent growth of breast cancer cells. This synergistic interaction is also observed wit...

Expand abstract

Authors: Balasis, M; Forinash, K; Chen, Y; Fulp, W; Coppola, D

• Publication status: Published
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
• Volume: 17
• Issue: 9
• Pages: 2852-2862
• Publication date: 2011-05-01
• DOI: 10.1158/1078-0432.ccr-10-2544
• EISSN: 1557-3265
• ISSN: 1078-0432
• Language: English
• Keywords: Enzyme Inhibitors; Humans; Animals; Drug Synergism; Oncogene Protein v-akt; Antineoplastic Combined Chemotherapy Protocols; Female; Breast Neoplasms; Disease Progression; Cell Line, Tumor; Genes, erbB-2; Mice; Mammary Neoplasms, Experimental; Carcinoma; Mice, Transgenic; Drug Evaluation, Preclinical; Farnesyltranstransferase; Tumor Burden